DURECT Corporation
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- DURECT Corporation develops epigenetic therapies targeting dysregulated DNA methylation to treat serious conditions including acute organ injury such as alcohol-associated hepatitis and metabolic dysfunction-associated steatohepatitis; its lead candidate larsucosterol (DUR-928), an oral small molecule epigenetic regulator, completed Phase 2b AHFIRM trial showing promising mortality benefits and advances toward Phase 3 registration; the company also offers long-acting injectable platforms including SABER and CLOUD for sustained release of small molecules, peptides and proteins; FDA-approved POSIMIR (bupivacaine) for post-surgical analgesia under exclusive U.S. license to Innocoll Pharmaceuticals with DURECT retaining ex-U.S. rights; research tools via ALZET osmotic pumps sold globally for preclinical animal studies; and royalties from partnered products including Methydur (extended-release methylphenidate for ADHD with Orient Pharma), PERSERIS (risperidone for schizophrenia with Indivior), and an ophthalmology product with Santen Pharmaceuticals. Founded in 1998 and headquartered in Cupertino, California, DURECT operates primarily in the U.S. with worldwide partnerships and focuses on biopharmaceutical development and drug delivery technologies for chronic diseases. In July 2025, DURECT entered a definitive merger agreement with Bausch Health Companies Inc., under which Bausch Health Americas acquired DURECT for $1.75 per share plus up to $350 million in larsucosterol sales milestones; Bausch Health completed the acquisition on September 11, 2025, establishing DURECT as its indirect wholly-owned subsidiary and expanding its liver disease portfolio; in November 2024, DURECT sold its ALZET product line to Lafayette Instrument Co. for $17.5 million.
Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio
Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio
Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025
Durect (DRRX) Reports Q2 Loss, Tops Revenue Estimates
DURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on Proposed Acquisition by Bausch Health
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of DURECT Corporation (NASDAQ: DRRX)
Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout
DRRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of DURECT Corporation Is Fair to Shareholders
Shareholder Alert: The Ademi Firm Investigates Whether DURECT Corporation Is Obtaining a Fair Price for Its Public Shareholders
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease
DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
DURECT Corporation (DRRX) Q4 2024 Earnings Call Transcript
Durect (DRRX) Reports Q4 Loss, Lags Revenue Estimates
DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update
DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence
Durect (DRRX) Upgraded to Strong Buy: Here's Why
New Strong Buy Stocks for January 9th